Arcutis Biotherapeutics Inc
ARQT17.380USD
-0.330-1.86%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
2.08BCap. mercado
PérdidaP/E TTM
Más Datos de Arcutis Biotherapeutics Inc Compañía
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Información de la empresa
Símbolo de cotizaciónARQT
Nombre de la empresaArcutis Biotherapeutics Inc
Fecha de salida a bolsaJan 31, 2020
Director ejecutivoMr. Todd Franklin Watanabe
Número de empleados342
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección3027 Townsgate Road
CiudadWESTLAKE VILLAGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal91361
Teléfono18054185006
Sitio Webhttps://arcutis.com/
Símbolo de cotizaciónARQT
Fecha de salida a bolsaJan 31, 2020
Director ejecutivoMr. Todd Franklin Watanabe
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
699.65K
-1.43%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
--
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.02K
-0.14%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
42.51K
+60.82%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
35.80K
-50.23%
Ms. Sue-Jean Lin
Ms. Sue-Jean Lin
Independent Director
Independent Director
26.73K
+39.78%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Independent Director
Independent Director
23.36K
+48.32%
Ms. Terrie J. Curran
Ms. Terrie J. Curran
Independent Director
Independent Director
--
--
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
917.81K
+0.84%
Mr. Todd Franklin Watanabe
Mr. Todd Franklin Watanabe
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
699.65K
-1.43%
Dr. Howard G. Welgus, M.D.
Dr. Howard G. Welgus, M.D.
Independent Director
Independent Director
100.21K
--
Ms. Latha Vairavan
Ms. Latha Vairavan
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
65.02K
-0.14%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Chairman of the Board
Independent Chairman of the Board
42.51K
+60.82%
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Mr. Masaru (Mas) Matsuda, Esq., J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
35.80K
-50.23%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
9.62%
Jennison Associates LLC
9.27%
Rubric Capital Management LP
8.96%
Frazier Life Sciences Management, L.P.
8.24%
BlackRock Institutional Trust Company, N.A.
6.35%
Otro
57.57%
Accionistas
Accionistas
Proporción
Suvretta Capital Management, LLC
9.62%
Jennison Associates LLC
9.27%
Rubric Capital Management LP
8.96%
Frazier Life Sciences Management, L.P.
8.24%
BlackRock Institutional Trust Company, N.A.
6.35%
Otro
57.57%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
31.48%
Investment Advisor
31.34%
Hedge Fund
30.46%
Private Equity
8.24%
Research Firm
5.91%
Individual Investor
2.14%
Venture Capital
1.80%
Bank and Trust
0.42%
Pension Fund
0.28%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
481
131.17M
109.40%
-22.25M
2025Q1
487
132.87M
111.51%
-24.00M
2024Q4
453
136.04M
114.96%
-23.73M
2024Q3
433
136.12M
116.66%
-19.10M
2024Q2
416
134.94M
116.78%
-20.37M
2024Q1
392
131.83M
115.81%
+2.26M
2023Q4
366
104.30M
108.66%
+5.22M
2023Q3
364
79.57M
131.78%
-15.32M
2023Q2
359
84.02M
139.44%
-6.66M
2023Q1
352
83.59M
140.11%
+3.40M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Suvretta Capital Management, LLC
11.42M
9.58%
+23.84K
+0.21%
Mar 31, 2025
Jennison Associates LLC
11.36M
9.53%
-978.92K
-7.93%
Mar 31, 2025
Rubric Capital Management LP
10.97M
9.2%
--
--
Mar 31, 2025
Frazier Life Sciences Management, L.P.
8.79M
7.37%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.91M
6.63%
-197.41K
-2.44%
Mar 31, 2025
The Vanguard Group, Inc.
6.79M
5.7%
+373.66K
+5.82%
Mar 31, 2025
Polar Capital LLP
6.71M
5.63%
-670.91K
-9.09%
Mar 31, 2025
State Street Global Advisors (US)
4.47M
3.75%
-476.52K
-9.63%
Mar 31, 2025
Gilder Gagnon Howe & Co. LLC
4.10M
3.44%
+193.06K
+4.95%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.08M
2.58%
-403.45K
-11.59%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
Simplify Health Care ETF
3.35%
SPDR S&P Biotech ETF
0.61%
Federated Hermes MDT Small Cap Core ETF
0.46%
First Trust Small Cap Growth AlphaDEX Fund
0.42%
Direxion Daily S&P Biotech Bull 3X Shares
0.35%
Invesco Nasdaq Biotechnology ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.19%
iShares Biotechnology ETF
0.16%
First Trust Small Cap Core Alphadex Fund
0.14%
Vanguard US Momentum Factor ETF
0.12%
Ver más
Simplify Health Care ETF
Proporción3.35%
SPDR S&P Biotech ETF
Proporción0.61%
Federated Hermes MDT Small Cap Core ETF
Proporción0.46%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.42%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.35%
Invesco Nasdaq Biotechnology ETF
Proporción0.2%
ProShares Ultra Nasdaq Biotechnology
Proporción0.19%
iShares Biotechnology ETF
Proporción0.16%
First Trust Small Cap Core Alphadex Fund
Proporción0.14%
Vanguard US Momentum Factor ETF
Proporción0.12%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
